Noctrix Health had developed a wearable neurostimulation device designed to treat moderate-to-severe restless legs syndrome through its proprietary TOMAC therapy, which works by delivering targeted electrical stimulation to the legs. The therapy represents a non-pharmacological treatment pathway for RLS, an area where treatment options have historically been limited and where patients often face challenges with long-term medication adherence or side effects. The acquisition of Noctrix Health is structured as an upfront payment combined with additional milestone-based consideration, with the total deal reaching up to $340 million depending on the achievement of certain commercial and regulatory milestones.

ResMed’s Chief Executive Officer Mick Farrell highlighted the strategic importance of the transaction, describing Noctrix Health’s TOMAC therapy as a meaningful addition to the company’s growing portfolio of sleep health solutions. ResMed, which is widely known for its continuous positive airway pressure (CPAP) devices and software solutions for sleep apnea management, has been actively broadening its reach across various sleep-related conditions. The inclusion of an RLS-focused therapy aligns directly with that broader strategic direction, allowing the company to address a wider spectrum of sleep disorders beyond its core sleep apnea business.

Restless legs syndrome affects a significant portion of the global population and is frequently underdiagnosed and undertreated. The condition causes uncomfortable sensations in the legs, typically worsening at night, and leads to severe disruptions in sleep. By integrating Noctrix Health’s technology and clinical expertise through the acquisition of Noctrix Health, ResMed positions itself to serve patients who have not yet found effective relief through existing treatment options. The combined organization is expected to continue development efforts and pursue broader commercialization of the TOMAC platform as part of ResMed’s long-term growth strategy in sleep health.

According to the organizations, the collaboration is designed to improve financial performance, streamline administrative activities and reinforce the connection between supply chain strategy and clinical priorities. TMH will retain decision-making authority and leadership oversight while benefiting from broader support in areas including strategic sourcing, purchased services optimization, analytics-driven decision making and clinical-supply alignment. The integrated approach is expected to enable multiple value-focused initiatives to move forward simultaneously, helping accelerate results while reducing pressure on internal teams. Speaking about the agreement, David Adkins, Executive Director of Supply Chain Management, Tallahassee Memorial HealthCare, said, “This partnership allows us to build on that momentum—adding scale, expertise and advanced analytics while preserving local ownership. It strengthens our ability to continuously improve and ensures we are well-positioned to serve our patients and community for the long term.”

A key aspect of the arrangement is TMH’s established culture of clinical collaboration, including physician champion support and experience with co-management models. These capabilities are expected to support closer integration between clinical stakeholders and supply chain planning. Bruce Mairose, Vice President of Inspirity Health Partners and Division Chair, Supply Chain Management at Mayo Clinic, stated, “TMH brings a disciplined approach and a clear commitment to continuous improvement. Together, we are building one fully integrated TMH–Inspirity supply chain team—seamlessly combining local expertise with national scale to deliver meaningful, sustainable value.” The organizations said the partnership reflects a broader movement among health systems seeking stronger operating performance while maintaining community-focused governance. Through advanced analytics, operational methodologies and national-scale resources, the collaboration is intended to create a resilient Healthcare Supply Chain platform that supports continued strategic growth.

InterSystems, a creative data technology provider dedicated to helping customers solve critical scalability, interoperability, and speed problems, today announced a new partnership with 59stVentures to enable more connected, interoperable, and AI-ready data ecosystems across ASEAN and the broader Asia-Pacific region.

The partnership combines the InterSystems global leadership in interoperable, high-performance data platforms and AI-ready architectures with 59stVentures’ industry transformation and regional digital innovation and execution capabilities, to help organisations integrate fragmented data and scale AI adoption.

Many organisations across ASEAN remain constrained by fragmented, siloed data spread across multiple systems and formats. This lack of interoperability limits the ability to generate unified insights, slowing down digital transformation efforts. Together, InterSystems and 59stVentures will tackle these barriers, empowering organisations to integrate, harmonise, and activate their data for scalable AI adoption, real-time analytics, and more informed decision-making.

AI-Ready Platforms for Healthcare, Supply Chain and Smart Cities

InterSystems data platforms – including InterSystems IRIS^® and InterSystems IRIS for Health™ – enable organisations to integrate and harmonise data across complex systems, support standards-based exchange such as HL7^® FHIR^® (Fast Healthcare Interoperability Resources), and build and customise their own AI-ready applications.

By aligning InterSystems technology with local market requirements, 59stVentures and its ecosystem-driven expertise will equip organisations to deploy interoperable, AI-ready data environments more efficiently. This will accelerate real-world adoption and ensure solutions are tailored to the diverse regulatory and operational contexts across the region.

Ultimately, the partnership aims to help​ enterprises and public sector agencies transition from reactive operations to truly predictive, adaptive, and resilient models. While healthcare is a cornerstone – particularly in enabling longitudinal medical records and system-wide visibility, the partnership will also extend to supply chain, logistics, and smart cities with the InterSystems Data Studio™ and InterSystems Supply Chain Orchestrator™ solutions providing unified data orchestration and harmonisation across diverse stakeholders.

“Across Southeast Asia, organisations are moving quickly to adopt AI in multiple industries, but many remain constrained by fragmented data. AI success depends not only on models, but on trusted, interoperable data ecosystems and strong industry collaboration,” said Jim Lim, Chief Strategy Officer and Managing Director of 59stVentures.” Together, we aim to help organisations across ASEAN operationalise AI in practical, scalable, and sustainable ways.”

“We are seeing strong momentum around AI across ASEAN,” said Luciano Brustia, Regional Managing Director, Asia Pacific, InterSystems. “Through this partnership, we are bringing global best practices into the region to help organisations accelerate AI adoption and deliver meaningful outcomes at scale.”

The two companies have merged Cercare Medical’s automated perfusion software with multiphase 3D acquisition protocols from Siemens Healthineers. On a technical level, this setup uses the vendor-neutral Cercare Medical Neurosuite to read perfusion maps and metabolic metrics directly inside the angiography suite. By connecting this software to the Syngo DynaCT Multiphase system, operators can generate up to ten cone-beam computed tomography phases for immediate review.

With these tools in place, medical staff can complete detailed stroke care imaging without having to move the patient to a different wing of the hospital.

Keeping a patient in the angiography room removes the typical requirement to transport them for standard magnetic resonance or computed tomography scans during the most critical acute window.

• Cutting down on patient transfers directly reduces procedural delays.
  Faster treatment decisions save millions of neurons that are otherwise lost each minute.
• During a thrombectomy, having instant data about cerebral blood flow and tissue viability gives operators the exact metrics they need to modify their approach on the spot.

Quick access to stroke care imaging makes it much easier to evaluate brain tissue health. The combined technology shows exactly how well different regions of the brain are receiving oxygen and essential nutrients. Because of this, clinical teams can spot microvascular issues, no-reflow occurrences, and distal occlusions right alongside the main thrombectomy procedure.

Clinical researchers who helped establish the scientific groundwork for this solution point out that having direct imaging in the intervention space ensures treatment can carry on seamlessly, even when conventional imaging machines are occupied or unavailable. This immediate line of sight ultimately helps predict clinical outcomes and assess any residual complications as they happen.

With qualitative perfusion technology now holding necessary regulatory clearances, both companies plan to scale their specialized offering globally, aiming to standardize how hospitals handle time-sensitive neurological emergencies.

This technological integration connects the surgical hardware to a wide range of Siemens Healthineers equipment, encompassing 1.5T, 3T, and the newer 0.55T MRI scanners, including the recently introduced MAGNETOM Free.XL. By establishing a direct software interface, the two entities facilitate robust data exchange and collaborative functionality between the devices. Building upon this foundational compatibility, AiM Medical Robotics plans to pursue deeper integration to continually enhance the efficiency of its robotic neurosurgery system.

The newly formed interface significantly boosts the clinical accessibility of complex image-guided therapies. This capability is particularly relevant for rapidly and accurately placing neurostimulator leads, conducting tumor and epilepsy ablation, performing biopsies, and delivering targeted therapeutics. By executing these tasks with real-time diagnostic guidance, clinical teams can elevate the standard of care while optimizing operational workflows.

• Real-time data exchange enhances in-bore precision for stereotactic interventions.
• Software compatibility covers a broad spectrum of diagnostic imaging environments.
• The collaboration sets the stage for next-generation automated medical treatments.

The initiative validates the growing ecosystem necessary to support sophisticated robotic neurosurgery. The combined efforts of AiM Medical Robotics and Siemens Healthineers establish a strong technical baseline, paving the way for future advancements in robotic neurosurgery and broader medical interventions.

The new office reinforces InterSystems commitment to Indonesia as a strategic growth market in Southeast Asia, enabling closer collaboration with customers, partners, and government stakeholders to address the country’s evolving data platform, interoperability, and digital infrastructure needs.

Indonesia’s digital economy is expanding rapidly, driven by strong growth in cloud computing, data platforms, and artificial intelligence (AI). Organizations across sectors are increasingly focused on integrating fragmented systems, unlocking real-time insights, and improving operational resilience through data-driven strategies.
This transformation is creating significant market opportunities. Across industries, demand is rising for high-performance data platforms that can support real-time analytics, seamless system integration, and AI-enabled decision-making.

InterSystems technologies, including the InterSystems IRIS® Data Platform and InterSystems IntelliCare™ unified healthcare information system, are deployed by organizations across Indonesia. The company works with enterprises, system integrators, and digital partners across financial services, logistics, and healthcare to enable interoperability, streamline operations, and support the adoption of AI.

“Indonesia is at an inflection point where organizations are looking to turn increasing volumes of data into actionable insight. There is a growing need for reliable, interoperable, and real-time data platforms that can support innovation at scale. The opening of our new Jakarta office reflects our long-term commitment to Indonesia and allows us to work more closely with customers and partners to help turn their ambitions into outcomes.” said Luciano Brustia, Regional Managing Director, Asia Pacific, InterSystems.

Priorities for the Expanded Local Presence

Through its expanded local presence, InterSystems is set to deepen engagement with its growing Indonesian customer base by delivering localized expertise and accelerating implementation timelines. The company will further strengthen collaboration with partners across financial services, supply chain, and healthcare sectors, while actively supporting national priorities around data integration, interoperability, and digital resilience.

InterSystems solutions address key challenges across industries, including data silos, fragmented systems, and the increasing need for real-time analytics to support operational and strategic decision-making. By enabling seamless data exchange and high-performance analytics, InterSystems helps organizations build more connected and resilient digital ecosystems.

InterSystems, a creative data technology provider powering more than one billion health records globally, today announced that its electronic health record (EHR) solutions have been certified as Class IIa Medical Devices under Regulation (MDR) certification under Regulation (EU) 2017/745. This approval marks the first fully unified AI-native EHR to achieve MDR Class IIa certification in the European Union.

This certification demonstrates that InterSystems AI-native EHR meets stringent EU safety and quality standards. This key milestone has significant implications for how healthcare organizations can responsibly scale AI while building confidence among healthcare providers and regulators.

InterSystems has secured MDR certification for InterSystems IntelliCare™, a next-generation EHR architected with native artificial intelligence capabilities, and InterSystems TrakCare®, a unified healthcare information system used by leading healthcare systems globally. Built on TrakCare’s proven interoperability foundation, InterSystems IntelliCare differentiates itself by delivering AI capabilities that are fundamentally designed into the platform’s data layer, rather than bolted on as third-party applications.

“Healthcare organizations are rightfully demanding that AI be more than just an experimental add-on,” said Don Woodlock, President, InterSystems. “By securing the EU’s first MDR certification for an AI-native EHR, we are establishing a standard that AI should be at the core of all healthcare applications”.

By moving beyond fragmented AI add-ons, InterSystems IntelliCare provides organizations with simplified oversight for their own governance, and clinicians with tools designed to reduce workload and burnout. The platform delivers instant patient summaries, AI‑driven clinical documentation, full chat experiences and intelligent workflows that maintain a critical “human-in-the-loop” safeguard. Features such as ambient clinical orchestration automatically capture, structure and save clinical data in real-time and suggest clinical documentation and orders for clinician approval. InterSystems IntelliCare also seamlessly connects with existing health IT infrastructures, leveraging InterSystems deep history in integration and data management capabilities.

Japan’s healthcare sector continues to face growing strain as the country’s aging population increases demand for medical services. Medical costs have risen beyond 48 trillion yen annually, while healthcare providers are dealing with staffing shortages, financial pressures, and broader sustainability concerns within the social security system. At the same time, medical data required for advanced clinical research remains insufficiently standardized and fragmented across institutions, limiting broader utilization. Fujitsu and IBM Japan said easing the administrative burden on healthcare workers and enabling more efficient use of medical data across organizations will be essential for improving care delivery. Under the collaboration, the companies will jointly promote operational efficiency initiatives while supporting medical DX measures encouraged by the Japanese government. Their sovereign cloud platform will serve as a common foundation for healthcare applications provided by both companies, enabling medical institutions to adopt cloud-based systems with stronger control over data management and security.

The companies also plan to integrate and jointly utilize their AI technologies for the healthcare industry. With consent from healthcare providers and patients, Fujitsu and IBM Japan aim to securely combine data from multiple medical institutions in Japan to improve clinical and operational workflows. Planned use cases include AI support for preparing clinical and nursing reports as well as streamlining DPC coding processes linked to medical fee claims. The collaboration is also exploring initiatives connected to drug discovery and clinical development, including identifying patients eligible for clinical trials and improving research efficiency. By expanding cooperation with university hospitals, national centers, and other medical institutions, the companies intend to validate healthcare data and AI applications before phased deployment. Medical AI will also support future patient-centric services covering appointment booking, treatment processes, and post-care follow-up.

The launch follows increasing use of artificial intelligence tools within hospital pharmacy environments. Bluesight’s 2026 research found that 24% of pharmacy leaders currently use AI every day, while 35% of diversion professionals already depend on tools such as ChatGPT and Microsoft Copilot to review controlled substance data. Prism Assistant was developed specifically for diversion monitoring workflows rather than general-purpose AI applications. The company stated that the platform functions entirely within its secure infrastructure, uses integrated ControlCheck data sources, and aligns with Google’s Secure AI Framework (SAIF). “Demand for generative AI in diversion monitoring is already here,” said Kevin MacDonald, CEO and co-founder of Bluesight. “But many teams are using tools that weren’t built for sensitive healthcare data or diversion workflows. Prism Assistant delivers the speed they need while keeping data secure and grounded in the workflows they already trust.”

Using Prism Assistant, diversion teams can request reports, graphs, and evidence-backed responses related to provider behavior and controlled substance trends in less than a minute. Bluesight said this allows staff to spend more time on higher-priority investigations, regulatory compliance activities, and diversion confirmation processes instead of manually assembling data. Twenty health systems are already deploying the assistant within ControlCheck for peer comparisons, executive reporting, and staff investigation analysis. Reported outcomes include recurring reports being completed 96% faster, pre-investigation triage reduced from three hours to around 10 minutes, and detailed variance analysis shortened from 30 minutes to under a minute. Bluesight also confirmed the Hospital AI Platform will expand into PrivacyPro later this year while the company develops agentic AI capabilities capable of handling multi-step workflows independently.